Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 1,236 shares of the stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $20.30, for a total value of $25,090.80. Following the sale, the insider now directly owns 77,099 shares in the company, valued at $1,565,109.70. This trade represents a 1.58 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Castle Biosciences Stock Performance
CSTL opened at $19.94 on Friday. The company's 50 day moving average is $24.19 and its 200 day moving average is $28.01. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. The company has a market cap of $558.46 million, a price-to-earnings ratio of 99.70 and a beta of 0.98. Castle Biosciences, Inc. has a 12-month low of $16.97 and a 12-month high of $35.84.
Wall Street Analysts Forecast Growth
CSTL has been the topic of several research analyst reports. Guggenheim set a $30.00 price target on shares of Castle Biosciences and gave the company a "buy" rating in a report on Friday. Robert W. Baird increased their price objective on shares of Castle Biosciences from $36.00 to $37.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. Finally, Stephens reaffirmed an "overweight" rating and issued a $41.00 target price on shares of Castle Biosciences in a research report on Thursday, January 2nd. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $38.75.
Check Out Our Latest Report on CSTL
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of CSTL. Wellington Management Group LLP purchased a new stake in shares of Castle Biosciences in the 4th quarter worth $19,244,000. Mackenzie Financial Corp bought a new stake in Castle Biosciences during the fourth quarter valued at about $560,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Castle Biosciences by 18.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 66,018 shares of the company's stock worth $1,759,000 after buying an additional 10,486 shares during the period. Two Sigma Advisers LP purchased a new position in shares of Castle Biosciences during the 4th quarter valued at about $306,000. Finally, Point72 Asset Management L.P. grew its stake in shares of Castle Biosciences by 9.6% during the 4th quarter. Point72 Asset Management L.P. now owns 547,104 shares of the company's stock valued at $14,580,000 after acquiring an additional 47,912 shares during the period. Hedge funds and other institutional investors own 92.60% of the company's stock.
Castle Biosciences Company Profile
(
Get Free Report)
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
